Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $130.49 USD
Change Today +2.41 / 1.88%
Volume 142.5K
BLUE On Other Exchanges
As of 10:45 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Nick Leschly

Chief Executive Officer, President and Director,bluebird bio, Inc.
AgeTotal Calculated CompensationThis person is connected to 15 board members in 1 different organizations across 3 different industries.

See Board Relationships
As of Fiscal Year 2014


Mr. Nick Leschly has been Chief Executive Officer and President at bluebird bio, Inc. (alternate name Genetix Pharmaceuticals Inc.) since September 2010. Mr. Leschly served as Interim President at bluebird bio, Inc. until September 2010. He served as Partner at Third Rock Ventures, LLC. He served as the Chief Business Officer of Agios Pharmaceuticals, Inc. Prior to joining Third Rock, he served as the product and alliance leader for Millennium Pharmaceuticals VELCADE™, ...

Read Full Background

Corporate Headquarters*

150 Second Street
Cambridge, Massachusetts 02141

United States

Phone: 339-499-9300
Fax: --

Board Members Memberships*

Chief Executive Officer, President and Director


Princeton University
University of Pennsylvania - The Wharton School

Other Affiliations*

Annual Compensation*

Total Annual Compensation$440,404

Stock Options*

Exercised Options116,266
Exercised Options Value$1,865,325
Exercisable Options264,280
Exercisable Options Value$22,997,942
Unexercisable Options486,985
Unexercisable Options Value$39,006,046
Total Value of Options$63,869,313
Total Number of Options867,531

Total Compensation*

Total Annual Cash Compensation$744,279
Total Short Term Compensation$440,404
Total Calculated Compensation$3,619,390
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLUE:US $130.18 USD +2.10


Edward O. Lanphier IIFounder, Chief Executive Officer, President, Director and Member of Clinical Review Committee
Sangamo Biosciences Inc.
David M. Pernock Chairman, Chief Executive Officer and President
Fibrocell Science, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BLUEBIRD BIO INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at